Sage Therapeutics halts Alzheimer's drug development due to mid-stage trial inefficacy.

Sage Therapeutics has halted development of its Alzheimer's drug, dalzanemdor, after a mid-stage trial failed to show significant efficacy compared to a placebo in treating mild cognitive impairment and mild dementia. This setback follows the discontinuation of another drug, zurzuvae, for clinical depression. Despite these challenges, Sage plans to continue testing dalzanemdor for Huntington's disease, with results expected later this year. The company's shares dropped about 12% following the announcement.

October 08, 2024
16 Articles